Skip to content
The Policy VaultThe Policy Vault

Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) — Medica

Alveolar Soft Part Sarcoma

Initial criteria

  • age ≥ 18 years
  • prescribed by or in consultation with an oncologist

Approval duration

1 year